Helen H Hobbs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6559208/publications.pdf

Version: 2024-02-01

83	29,138	23500 58	58464 82
papers	citations	h-index	g-index

86	86	86	23980
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 879-899.	2.3	36
2	Contribution of a genetic risk score to ethnic differences in fatty liver disease. Liver International, 2022, 42, 2227-2236.	1.9	16
3	Genetic and Metabolic Determinants of Plasma Levels of ANGPTL8. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1649-1667.	1.8	15
4	Molecular basis of cholesterol efflux via ABCG subfamily transporters. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	44
5	Beth Levine M.D. Prize in Autophagy Research. Autophagy, 2021, 17, 2053-2053.	4.3	0
6	Missense variant in insulin receptor (Y1355H) segregates in family with fatty liver disease. Molecular Metabolism, 2021, 53, 101299.	3.0	1
7	Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. Journal of Lipid Research, 2020, 61, 1271-1286.	2.0	120
8	ANGPTL8 has both endocrine and autocrine effects on substrate utilization. JCI Insight, 2020, 5, .	2.3	48
9	Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9521-9526.	3.3	182
10	PNPLA3, CGIâ€58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice. Hepatology, 2019, 69, 2427-2441.	3.6	129
11	Increased thermogenesis by a noncanonical pathway in ANGPTL3/8-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1249-E1258.	3.3	39
12	Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride. Hepatology, 2018, 67, 2182-2195.	3.6	51
13	A Protein-TruncatingHSD17B13Variant and Protection from Chronic Liver Disease. New England Journal of Medicine, 2018, 378, 1096-1106.	13.9	556
14	Patatin-like phospholipase domainâ€“containing protein 3 promotes transfers of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. Journal of Biological Chemistry, 2018, 293, 6958-6968.	1.6	74
15	HSD17B13 and Chronic Liver Disease in Blacks and Hispanics. New England Journal of Medicine, 2018, 379, 1876-1877.	13.9	39
16	Science, serendipity, and the single degree. Journal of Clinical Investigation, 2018, 128, 4218-4223.	3.9	2
17	Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nature Genetics, 2017, 49, 842-847.	9.4	288
18	ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. Journal of Lipid Research, 2017, 58, 1166-1173.	2.0	152

#	Article	IF	Citations
19	ANGPTL8 Blockade With a Monoclonal Antibody Promotes Triglyceride Clearance, Energy Expenditure, and Weight Loss in Mice. Endocrinology, 2017, 158, 1252-1259.	1.4	59
20	The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology, 2017, 66, 1111-1124.	3.6	198
21	Variability of cholesterol accessibility in human red blood cells measured using a bacterial cholesterol-binding toxin. ELife, 2017, 6, .	2.8	44
22	Reply. Hepatology, 2016, 63, 677-677.	3.6	1
23	Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins. Journal of Biological Chemistry, 2016, 291, 10659-10676.	1.6	172
24	Crystal structure of the human sterol transporter ABCG5/ABCG8. Nature, 2016, 533, 561-564.	13.7	233
25	Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology, 2015, 61, 108-118.	3.6	297
26	Adult-onset liver disease and hepatocellular carcinoma in S-adenosylhomocysteine hydrolase deficiency. Molecular Genetics and Metabolism, 2015, 116, 269-274.	0.5	37
27	Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. Journal of Lipid Research, 2015, 56, 1296-1307.	2.0	153
28	ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. Journal of Lipid Research, 2015, 56, 1308-1317.	2.0	165
29	Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11630-11635.	3.3	109
30	Relative roles of ABCG5/ABCG8 in liver and intestine. Journal of Lipid Research, 2015, 56, 319-330.	2.0	122
31	Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways. ELife, 2015, 4, e07999.	2.8	143
32	Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2014, 46, 352-356.	9.4	938
33	ANGPTL8/Betatrophin Does Not Control Pancreatic Beta Cell Expansion. Cell, 2014, 159, 691-696.	13.5	187
34	APOC3, Coronary Disease, and Complexities of Mendelian Randomization. Cell Metabolism, 2014, 20, 387-389.	7.2	34
35	Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16109-16114.	3.3	281
36	Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. Journal of Lipid Research, 2012, 53, 1932-1943.	2.0	92

#	Article	IF	Citations
37	Atypical angiopoietin-like protein that regulates ANGPTL3. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19751-19756.	3.3	375
38	Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology. Hepatology, 2012, 55, 1139-1145.	3.6	34
39	Deletion of GPIHBP1 causing severe chylomicronemia. Journal of Inherited Metabolic Disease, 2012, 35, 531-540.	1.7	80
40	Genetic variant inPNPLA3is associated with nonalcoholic fatty liver disease in China. Hepatology, 2012, 55, 327-328.	3.6	37
41	Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. Journal of Clinical Investigation, 2012, 122, 4130-4144.	3.9	221
42	Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523.	6.0	1,780
43	Dissociation betweenAPOC3variants, hepatic triglyceride content and insulin resistance. Hepatology, 2011, 53, 467-474.	3.6	122
44	Hepatic triglyceride content in individuals with reduced intestinal cholesterol absorption due to variants in Nieman Pick C1-like 1. Hepatology, 2011, 54, 736-737.	3.6	2
45	Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease. Journal of Biological Chemistry, 2011, 286, 37085-37093.	1.6	240
46	Sequences in the Nonconsensus Nucleotide-binding Domain of ABCG5/ABCG8 Required for Sterol Transport. Journal of Biological Chemistry, 2011, 286, 7308-7314.	1.6	29
47	Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1189-1192.	3.6	32
48	A feed-forward loop amplifies nutritional regulation of PNPLA3. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7892-7897.	3.3	319
49	A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis. Journal of Biological Chemistry, 2010, 285, 6706-6715.	1.6	507
50	Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 800-809.	1.8	70
51	Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia. New England Journal of Medicine, 2010, 363, 2220-2227.	13.9	640
52	Genetic Variation in ANGPTL4 Provides Insights into Protein Processing and Function. Journal of Biological Chemistry, 2009, 284, 13213-13222.	1.6	112
53	Genetic and Metabolic Determinants of Plasma PCSK9 Levels. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2537-2543.	1.8	434
54	PCSK9: a convertase that coordinates LDL catabolism. Journal of Lipid Research, 2009, 50, S172-S177.	2.0	517

#	Article	IF	Citations
55	Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. Journal of Clinical Investigation, 2009, 119, 70-9.	3.9	322
56	Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2008, 40, 1461-1465.	9.4	2,764
57	Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13045-13050.	3.3	199
58	Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. Journal of Biological Chemistry, 2007, 282, 18602-18612.	1.6	660
59	Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nature Genetics, 2007, 39, 513-516.	9.4	473
60	Molecular biology of PCSK9: its role in LDL metabolism. Trends in Biochemical Sciences, 2007, 32, 71-77.	3.7	512
61	Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. Journal of Clinical Investigation, 2007, 117, 165-174.	3.9	51
62	Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote. American Journal of Human Genetics, 2006, 79, 514-523.	2.6	578
63	A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol. American Journal of Human Genetics, 2006, 78, 410-422.	2.6	495
64	Functional Asymmetry of Nucleotide-binding Domains in ABCG5 and ABCG8. Journal of Biological Chemistry, 2006, 281, 4507-4516.	1.6	44
65	Sterol Transfer by ABCG5 and ABCG8. Journal of Biological Chemistry, 2006, 281, 27894-27904.	1.6	72
66	Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genetics, 2005, 37, 161-165.	9.4	1,246
67	Expression of ABCG5 and ABCG8 Is Required for Regulation of Biliary Cholesterol Secretion. Journal of Biological Chemistry, 2005, 280, 8742-8747.	1.6	191
68	Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E462-E468.	1.8	1,323
69	Selective sterol accumulation in ABCG5/ABCG8-deficient mice. Journal of Lipid Research, 2004, 45, 301-307.	2.0	123
70	No Association Between Plasma Levels of Plant Sterols and Atherosclerosis in Mice and Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2326-2332.	1.1	167
71	The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. American Journal of Cardiology, 2004, 93, 1473-1480.	0.7	472
72	Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology, 2004, 40, 1387-1395.	3.6	3,250

#	Article	IF	Citations
73	ABCG5 and ABCG8 Are Obligate Heterodimers for Protein Trafficking and Biliary Cholesterol Excretion. Journal of Biological Chemistry, 2003, 278, 48275-48282.	1.6	401
74	Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16237-16242.	3.3	645
75	Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. Journal of Lipid Research, 2002, 43, 486-494.	2.0	199
76	Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. Journal of Clinical Investigation, 2002, 110, 659-669.	3.9	252
77	Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Human Mutation, 2001, 18, 359-360.	1.1	149
78	High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nature Medicine, 2001, 7, 853-857.	15.2	675
79	Accumulation of Dietary Cholesterol in Sitosterolemia Caused by Mutations in Adjacent ABC Transporters. , 2000, 290, 1771-1775.		1,412
80	High plasma levels of apo(a) fragments in Caucasians and Africanâ€Americans with endâ€stage renal disease: implications for plasma Lp(a) assay. Clinical Genetics, 1997, 52, 387-392.	1.0	18
81	Expression of the VLDL Receptor in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 407-415.	1.1	120
82	Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Human Mutation, 1992, 1, 445-466.	1.1	1,045
83	The LDL Receptor Locus in Familial Hypercholesterolemia: Mutational Analysis of a Membrane Protein. Annual Review of Genetics, 1990, 24, 133-170.	3.2	655